MedTrace Logo

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

NCT00214773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 237

Last updated 2021-04-05

No results posted yet for this study

Summary

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

Conditions

  • Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

Sponsors & Collaborators

Principal Investigators

  • Julie Johnson · BioMarin Pharmaceutical

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • France
  • Germany
  • Ireland
  • Italy
  • Lithuania
  • Netherlands
  • Portugal
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214773 on ClinicalTrials.gov